Joaquín
Casal Rubio
Hospital de Sagunto
Sagunto, EspañaPublicacións en colaboración con investigadores/as de Hospital de Sagunto (3)
2014
-
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 160-166
-
Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: A multi-center phase II study
Anticancer Research, Vol. 34, Núm. 4, pp. 1959-1966
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81